< Back to Publications & Resources
Elevate Your Practice: Curated Insights for Your Medical Office
Navigating the ever-expanding volume of information in the medical field can be a daunting task. How do you efficiently discern critical insights that truly make a difference in your daily practice? At MLMIC, we recognize this challenge. That's why we have meticulously compiled a selection of vital articles, providing you with clear, concise summaries and direct access to the most impactful industry news and analysis. Think of this as your essential guide to staying sharp and comprehensively informed.
Join us as we explore our curations for the month of September.
Simple Blood Tests May Help Flag Colorectal Cancer in Young Adults
A new analysis from Epic Research found that adults under age 45 with lower levels of the liver enzymes AST (aspartate transaminase) and ALT (alanine transaminase) were more likely to be diagnosed with early-onset colorectal cancer than their peers. Researchers noted that this finding was unexpected because doctors typically focus on elevated, not low, liver enzyme levels.
Importantly, the study found only an association, not a cause-and-effect relationship. Experts emphasize that low AST and ALT levels do not mean someone will develop colorectal cancer, nor do they warrant changes to current colorectal cancer screening recommendations. The findings may help researchers better understand why colorectal cancer rates are increasing among younger adults and could point to underlying factors such as muscle mass, nutrition or overall health status.
Early Trial Suggests AI-designed Drug May Reverse Signs of Biological Aging
A new Phase 2a clinical trial found that rentosertib, an AI-designed drug originally developed to treat idiopathic pulmonary fibrosis (IPF), reduced several markers of biological age in patients over a 12-week period. Researchers analyzed blood samples from 42 participants using six different "aging clocks," all of which suggested a decrease in predicted biological age among those taking the drug.
The study's authors emphasize that the findings are preliminary and do not prove the drug actually slows or reverses aging. Because the participants had a chronic lung disease, it's unclear whether the improvement in aging biomarkers reflects a true anti-aging effect or simply better overall health resulting from treatment of the underlying disease.
Researchers say the ultimate goal is not just extending lifespan but increasing health span, meaning the number of years people remain healthy, active and free from serious disease. The study also highlights the growing role of AI in drug discovery, from identifying potential drug targets to designing new compounds and analyzing clinical trial data.
New Hope in the Treatment of Pancreatic Cancer
Optimism is growing in the fight against pancreatic cancer, one of the deadliest forms of cancer. A major reason for that optimism is daraxonrasib, a new targeted drug that, in a clinical trial, doubled the survival time of patients with advanced pancreatic cancer, prompting some experts to call it one of the most significant breakthroughs in the disease's history.
The article explains that pancreatic cancer has long been difficult to treat due to late diagnosis, limited treatment options, and poor response to many newer cancer therapies. Researchers are now seeing promise not only from daraxonrasib and similar drugs targeting KRAS mutations, but also from emerging approaches such as mRNA-based vaccines and next-generation immunotherapies.
Dive deeper.
How Rural Hospitals are Building Up Reserves
Rural hospitals are working to strengthen their cash reserves by improving revenue cycle operations, closely managing expenses, being more strategic with capital investments and seeking grants and other external funding sources. Hospital leaders say efforts such as streamlining insurance authorizations, reducing claim denials, monitoring reimbursement trends and carefully prioritizing technology and equipment purchases are helping improve financial stability.
Despite these efforts, rural providers continue to face significant challenges, including staffing shortages, reimbursement pressures and uncertainty surrounding government funding programs. Leaders noted that maintaining healthy cash reserves requires both operational discipline and a reimbursement environment that adequately supports the essential healthcare services rural communities rely on.
Why Patients are Turning to Chatbots for Medical Advice.
This article explores why more patients are turning to AI chatbots for medical information, citing factors such as convenience, immediate access to answers, lower costs and the ability to better understand symptoms, diagnoses, lab results and treatment options. Many users find chatbot-generated health information helpful and appreciate having a readily available source of guidance between medical appointments.
At the same time, experts caution that AI tools should supplement, not replace, professional medical care. While chatbots can improve health literacy and help patients prepare for conversations with their healthcare providers, concerns remain about accuracy, privacy, and the potential for incorrect or misleading medical advice
Follow us on LinkedIn, Twitter, Facebook or Instagram to stay in the loop about the medical professional liability industry.
If you are not already a MLMIC insured, learn more about us here.
This document is for general purposes only and should not be construed as medical, dental, or legal advice. This document is not comprehensive and does not cover all possible factual circumstances. Because the facts applicable to your situation may vary, or the laws applicable in your jurisdiction may differ, please contact your attorney or other professional advisors for any questions related to legal, medical, dental, or professional obligations, the applicable state or federal laws or other professional questions.
